Portland, OR -- (SBWIRE) -- 11/07/2017 -- Neuropeptide Y (NPY) receptors are involved in different types of biological processes. It is a class of G-Protein coupled receptors sensitive to closely associated peptide hormones such as peptide YY, pancreatic polypeptide, and neuropeptide Y. NPY is closely related to central mechanism involving obesity and food intake; however the topic is still a part of extensive medical research.
Increase in prevalence of various diseases related to obesity and surge in overweight populace drives the market. Moreover, unhealthy urban lifestyle and increase in number of fast food eating populace susceptible to sudden weight gain, is expected to boost the market growth. However, number of limited manufacturers and distribution channels is anticipated to impede the market growth.
Get TOC and sample copy: https://www.alliedmarketresearch.com/request-toc-and-sample/3681
The global neuropeptide Y receptor market is segmented on the basis of product, application, and geography. Based on product, the market is bifurcated into food grade and pharmaceutical grade. Based on application, it is divided into medicines, food additives, and others. By geography, it is analyzed across North America, Europe, Asia Pacific, and LAMEA. These regions are further analyzed across the globe at country level to determine the market size and forecast for each segment and sub-segment.
Comprehensive competitive analysis and profiles of major market players such Gila Therapeutics Inc, Novo Nordisk A/S, XL-protein GmbH, Lilly Eli & Co, Novartis AG, Pfizer Inc, Merck & Co., Inc., Mannkind Corp, Gilead Sciences Inc, and Genentech, Inc.as are provided in this report.
Some Key Benefits:
-The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
-Extensive analysis of the market is conducted by following key product positioning and monitoring the top competitors within the market framework.
-It offers a quantitative analysis from 2017 to 2023 to enable the stakeholders to capitalize on the prevailing market opportunities.
Customize report as per your requirement: https://www.alliedmarketresearch.com/request-for-customization/3681